Search results
Pfizer gene therapy for Duchenne fails to meet goals of key trial
BioPharma Dive via Yahoo Finance· 6 days agoThe negative results from the Phase 3 study, called Ciffreo, come a little more than a month after ...
Will Pfizer Stock Rebound To Its 2021 Highs Of $60?
Forbes· 2 days agoPfizer stock (NYSE: PFE) currently trades at $28 per share, 55% below its peak level of $61 seen in December 2021. PFE stock was trading at $52 in early June 2022, just before ...
Pfizer: An Oversold Pharma Stock in Recovery
GuruFocus.com via Yahoo Finance· 7 days agoSome say the art of investing is the ability of catching falling knives. Pfizer Inc. (NYSE:PFE) shares have sold off in 2023 and represent an attractive...
Greenwood Capital Associates LLC Purchases 11,853 Shares of Pfizer Inc. (NYSE:PFE)
ETF DAILY NEWS· 2 days agoGreenwood Capital Associates LLC grew its position in Pfizer Inc. (NYSE:PFE – Free Report) by 6.8% in the fourth quarter, HoldingsChannel.com reports. The fund owned 184,926 ...
Merck’s vaccine approval poses threat to one of Pfizer’s top-selling products
Market Watch· 1 day ago“We’ll provide protection that’s broader than anything that’s out there,” Art Hirt, senior vice...
MSD competes with Pfizer in pneumococcal vaccine market after FDA approval
Pharmaceutical Technology via Yahoo Finance· 11 hours agoThis includes the eight unique serotypes, 15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B compared to other...
Merck's vaccine approval poses threat to one of Pfizer's top-selling products
Morningstar· 1 day agoMerck & Co. Inc. on Monday gained U.S. regulatory approval for a vaccine that could become a tough competitor to one of Pfizer Inc.'s top-selling products. The Food and Drug ...
Pfizer Failure in Duchenne Muscular Dystrophy Trial Leaves Field Open for a Rival
Barrons.com· 5 days agoPfizer disclosed on May 7 that a child participating in another...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 6 days agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
Pfizer reports data from Phase II multiple myeloma treatment trial
Clinical Trials Arena via Yahoo Finance· 2 days agoPfizer has announced findings from the Phase II MagnetisMM-3 clinical trial of ELREXFIO...